Medicine
fromwww.theguardian.com
3 days agoTreatment that can double bladder cancer survival rates available to 1,000 patients in England
Enfortumab vedotin combined with pembrolizumab approved on the NHS in England doubles survival and will be offered to about 1,250 metastatic bladder cancer patients.